333 related articles for article (PubMed ID: 22948263)
1. A prospective evaluation of pulmonary, systemic and hepatic haemodynamics in HIV-HCV-coinfected patients before and after antiviral therapy with pegylated interferon and ribavirin.
Reiberger T; Payer BA; Ferlitsch A; Sieghart W; Breitenecker F; Aichelburg MC; Schmied B; Rieger A; Trauner M; Peck-Radosavljevic M;
Antivir Ther; 2012; 17(7):1327-34. PubMed ID: 22948263
[TBL] [Abstract][Full Text] [Related]
2. Liver fibrosis progression in HIV-HCV-coinfected patients treated with distinct antiretroviral drugs and impact of pegylated interferon/ribavirin therapy.
Fernández-Montero JV; Barreiro P; Vispo E; Labarga P; Sánchez-Parra C; de Mendoza C; Treviño A; Soriano V
Antivir Ther; 2014; 19(3):287-92. PubMed ID: 24192598
[TBL] [Abstract][Full Text] [Related]
3. Antiretroviral therapy and sustained virological response to HCV therapy are associated with slower liver fibrosis progression in HIV-HCV-coinfected patients: study from the ANRS CO 13 HEPAVIH cohort.
Loko MA; Bani-Sadr F; Valantin MA; Lascoux-Combe C; Fontaine H; Bonnard P; Gervais A; Bouchaud O; Garipuy D; Quertainmont Y; Vittecoq D; Tehrani MS; Winnock M; Dabis F; Salmon D;
Antivir Ther; 2012; 17(7):1335-43. PubMed ID: 23052829
[TBL] [Abstract][Full Text] [Related]
4. HIV-HCV co-infected patients with low CD4+ cell nadirs are at risk for faster fibrosis progression and portal hypertension.
Reiberger T; Ferlitsch A; Sieghart W; Kreil A; Breitenecker F; Rieger A; Schmied B; Gangl A; Peck-Radosavljevic M
J Viral Hepat; 2010 Jun; 17(6):400-9. PubMed ID: 19780945
[TBL] [Abstract][Full Text] [Related]
5. Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study.
Kovari H; Russmann S; Ledergerber B; Müller D; Rotger M; Velli P; Cavassini M; Ambrosioni J; Bregenzer A; Stöckle M; Bernasconi E; Rauch A; Speck RF;
PLoS One; 2015; 10(7):e0133879. PubMed ID: 26218843
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
Soriano V; Núñez M; Camino N; Maida I; Barreiro P; Romero M; Martin-Carbonero L; Garcia-Samaniego J; González-Lahoz J
Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081
[TBL] [Abstract][Full Text] [Related]
7. The association of cytopenias and weight loss with hepatitis C virus virologic response in HIV/HCV-coinfected patients treated with PEG-IFN and RBV.
Slim J; Mildvan D; Han J; Korner E
J Int Assoc Provid AIDS Care; 2013; 12(5):354-62. PubMed ID: 23873217
[TBL] [Abstract][Full Text] [Related]
8. Low vitamin D levels are associated with impaired virologic response to PEGIFN + RBV therapy in HIV-hepatitis C virus coinfected patients.
Mandorfer M; Reiberger T; Payer BA; Ferlitsch A; Breitenecker F; Aichelburg MC; Obermayer-Pietsch B; Rieger A; Trauner M; Peck-Radosavljevic M;
AIDS; 2013 Jan; 27(2):227-32. PubMed ID: 23238552
[TBL] [Abstract][Full Text] [Related]
9. Short communication: impact of hepatitis C viral clearance on CD4+ T-lymphocyte course in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin.
Milazzo L; Foschi A; Mazzali C; Viola A; Ridolfo A; Galli M; Antinori S
AIDS Res Hum Retroviruses; 2012 Sep; 28(9):989-93. PubMed ID: 22220723
[TBL] [Abstract][Full Text] [Related]
10. Changes in liver fibrosis in HIV/HCV-coinfected patients following different outcomes with peginterferon plus ribavirin therapy.
Labarga P; Fernandez-Montero JV; Barreiro P; Pinilla J; Vispo E; de Mendoza C; Plaza Z; Soriano V
J Viral Hepat; 2014 Jul; 21(7):475-9. PubMed ID: 24750394
[TBL] [Abstract][Full Text] [Related]
11. HCV clearance and treatment outcome in genotype 1 HCV-monoinfected, HIV-coinfected and liver transplanted patients on peg-IFN-alpha-2b/ribavirin.
Moreno A; Bárcena R; García-Garzón S; Muriel A; Quereda C; Moreno L; Mateos ML; Fortún J; Martín-Dávila P; García M; Blesa C; Otón E; Moreno A; Moreno S
J Hepatol; 2005 Nov; 43(5):783-90. PubMed ID: 16084622
[TBL] [Abstract][Full Text] [Related]
12. Differences in liver fibrosis and response to pegylated interferon plus ribavirin in HIV/HCV-coinfected patients with normal vs elevated liver enzymes.
Maida I; Martin-Carbonero L; Sotgiu G; Vispo E; Barreiro P; Gonzalez-Lahoz J; Soriano V
J Viral Hepat; 2010 Dec; 17(12):866-71. PubMed ID: 20088891
[TBL] [Abstract][Full Text] [Related]
13. Ribavirin and interferon alter MMP-9 abundance in vitro and in HIV-HCV-coinfected patients.
Kennedy A; Hennessy M; Bergin C; Mulcahy F; Hopkins S; Spiers JP
Antivir Ther; 2011; 16(8):1237-47. PubMed ID: 22155905
[TBL] [Abstract][Full Text] [Related]
14. [Clinical efficacy of pegylated interferon in patients co-infected with HIV and HCV who failed standard interferon therapy].
Ke YC; Li LH; Hu FY; He Y; Lan Y; Chen XJ; Tang XP; Cai WP
Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):181-5. PubMed ID: 27095760
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia.
Mira JA; Neukam K; López-Cortés LF; Rivero-Juárez A; Téllez F; Girón-González JA; de los Santos-Gil I; Ojeda-Burgos G; Merino D; Ríos-Villegas MJ; Collado A; Torres-Cornejo A; Macías J; Rivero A; Pérez-Pérez M; Pineda JA; ;
Eur J Clin Microbiol Infect Dis; 2015 Sep; 34(9):1879-84. PubMed ID: 26115631
[TBL] [Abstract][Full Text] [Related]
16. Interferon-free regimens improve portal hypertension and histological necroinflammation in HIV/HCV patients with advanced liver disease.
Schwabl P; Mandorfer M; Steiner S; Scheiner B; Chromy D; Herac M; Bucsics T; Hayden H; Grabmeier-Pfistershammer K; Ferlitsch A; Oberhuber G; Trauner M; Peck-Radosavljevic M; Reiberger T
Aliment Pharmacol Ther; 2017 Jan; 45(1):139-149. PubMed ID: 27910154
[TBL] [Abstract][Full Text] [Related]
17. Long-term survival and liver-related events after pegylated interferon/ribavirin therapy in HIV-infected patients with chronic hepatitis C.
Labarga P; Fernández-Montero JV; de Mendoza C; Barreiro P; Soriano V
Antivir Ther; 2015; 20(1):65-72. PubMed ID: 25105286
[TBL] [Abstract][Full Text] [Related]
18. Documented rapid course of hepatic fibrosis between two biopsies in patients coinfected by HIV and HCV despite high CD4 cell count.
Bonnard P; Lescure FX; Amiel C; Guiard-Schmid JB; Callard P; Gharakhanian S; Pialoux G
J Viral Hepat; 2007 Nov; 14(11):806-11. PubMed ID: 17927617
[TBL] [Abstract][Full Text] [Related]
19. Health-related quality of life and severity of fatigue in HIV/HCV co-infected patients before, during, and after antiviral therapy with pegylated interferon plus ribavirin.
Mandorfer M; Payer BA; Scheiner B; Breitenecker F; Aichelburg MC; Grabmeier-Pfistershammer K; Rieger A; Trauner M; Peck-Radosavljevic M; Reiberger T
Liver Int; 2014 Jan; 34(1):69-77. PubMed ID: 23890125
[TBL] [Abstract][Full Text] [Related]
20. HCV clearance from saliva of HIV-HCV-coinfected patients on treatment with interferon plus ribavirin.
Feijoo J; Eirea M; Limeres J; Abeleira M; Ramos I; Ocampo A; Diz P
Oral Dis; 2014 Apr; 20(3):313-8. PubMed ID: 23607445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
